Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Your DNA is continually damaged by sources both inside and outside your body. One especially severe form of damage called a ...

CRISPR Gene editing therapy is used for the first time in living humans with amazing results.

NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said on Monday that the investment ...

In the first half of 2025, eight systems have performed first-of-their-kind procedures and clinical treatments. 1. Morgantown, W.Va.-based WVU Heart and Vascular Institute physicians completed the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, ...

Scope Biosciences, a deep tech spin-off from Wageningen University & Research, has secured a follow-on investment from SHIFT ...

Japanese researchers have successfully eliminated the extra chromosome responsible for Down syndrome using CRISPR gene ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each ...